FIELD: chemistry; pharmaceutics.
SUBSTANCE: present invention relates to a solid pharmaceutical composition for treating malignant tumours, including malignant tumours in the larynx, thyroid gland, perspiratory glands, kidneys, prostate gland, Hodgkin's disease, non-Hodgkin's lymphoma and leucosis, containing an effective amount of the crystalline form of suberoylanilide hydroxamic acid (SAHA), obtained through a method which involves recystallisation of an unrefined SAHA preparation from a mixture of methanol and water in ratio of approximately 2:1, and a carrier.
EFFECT: obtaining a solid pharmaceutical composition for treating malignant tumours.
9 cl, 20 tbl, 14 dwg, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF FINAL DIFFERENTIATION INDUCTION | 2010 |
|
RU2530648C2 |
| METHOD OF INDUCTION OF TERMINAL DIFFERENTIATION | 2003 |
|
RU2320331C2 |
| COMBINATIONS OF SPECIFIC CLASS I HISTONE DEACETYLASE INHIBITORS AND PROTEASOME INHIBITORS | 2007 |
|
RU2456990C2 |
| COMBINATION OF A HISTONE DEACETYLASE INHIBITOR AND A PROTEIN KINASE INHIBITOR AND PHARMACEUTICAL APPLICATION THEREOF | 2019 |
|
RU2770754C1 |
| METHODS OF REDUCING CACHEXIA ASSOCIATED WITH CANCER | 2014 |
|
RU2692785C1 |
| METHODS AND COMPOSITIONS FOR TREATING TUMORS | 2017 |
|
RU2741786C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING HDAC INHIBITOR AND ANTI-PD1 ANTIBODY OR ANTI-PD-L1 ANTIBODY | 2020 |
|
RU2824577C1 |
| DOSAGE FORMS OF HISTONE DEACETYLASE INHIBITOR IN COMBINATION WITH BENDAMUSTINE AND THEIR APPLICATION | 2011 |
|
RU2609833C2 |
| HYSTONE DESACETYLASE INHIBITORS FROM NOVEL BENZAMIDE DERIVATIVES WITH STRONG DIFFERENTIAL ANTI-PROLOFERATIVE ACTIVITY | 2004 |
|
RU2364589C2 |
| METHODS FOR CANCER TREATMENT USING AUTOPHAGY INHIBITOR BASED ON THIOXANTHONE | 2011 |
|
RU2627588C2 |
